Optiscan Imaging Ltd (ASX: OIL) Share Price and News

Price

 

Movement

   

  (20 mins delayed)

52 Week Range

  -  

 
1 Year Return

 

Optiscan Imaging Ltd Chart and Price Data

Fundamentals Data provided by Morningstar.

Data provided by Morningstar.
Market Cap $162.07 million
P/E Ratio N/A
Dividend Yield 0.00%
Shares Outstanding 1.05 billion
Earnings per share -0.007
Dividend per share N/A
Year To Date Return 55.00%
Earnings Yield N/A
Franking -
Share Price

Day Change

52 Week Range

-

Yesterday's Close

Today's Open

Days Range

-

Volume

Avg. Volume (1 month)

Turnover

as at 24 Feb 3:44pm

  • Optiscan Imaging Ltd (ASX: OIL)
    Latest News

    A drawing of a white rocket streaking up, indicating a surging share pirce movement
    ASX Share Market News

    Why the OptiScan (ASX:OIL) share price is rocketing 26% today

    The OptiScan Imaging Limited (ASX: OIL) share price is rocketing 26% after announcing the appointment of a experienced industry executive.

    Read more »

    research with microscope
    ASX Share Market News

    Why the Optiscan (ASX:OIL) share price is going gangbusters

    The Optiscan share price is flying today as the company announced the next stage of its breast cancer study.

    Read more »

    ASX Share Market News

    Why the OptiScan (ASX:OIL) share price is climbing higher

    The Optiscan Imaging Ltd (ASX: OIL) share price is up 4.35% today after a positive announcement on a product order.

    Read more »

    woman looking up as if watching asx share price
    ASX Share Market News

    Optiscan (ASX:OIL) share price flat on FDA update

    The Optiscan Imaging Limited (ASX: OIL) share price is flat today despite FDA advice. Let's look at what's ahead for…

    Read more »

    OIL ASX Announcements

    An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.

    DateAnnouncementPrice Sensitive?TimeNo. of PagesFile Size
    YesNo

    About Optiscan Imaging Ltd

    Optiscan Imaging Ltd. is engaged in the development of endomicroscopic imaging technologies for medical, translational and pre-clinical applications. It has developed and patented miniaturised confocal microscopes. Its products include FIVE2 and Customisation options. The company was founded by Martin Harris and Peter Maxwell Delaney in 1994 and is headquartered in Mulgrave, Australia.

    OIL Share Price History Data provided by Morningstar.

    Data provided by Morningstar.
    Date Close Change % Change Volume Open High Low
    16 Nov 2026 $0.16 $0.00 0.00% 90,549 $0.16 $0.16 $0.15
    13 Nov 2026 $0.16 $0.00 0.00% 43,104 $0.16 $0.16 $0.16
    12 Nov 2026 $0.16 $0.00 0.00% 45,649 $0.16 $0.16 $0.16
    11 Nov 2026 $0.16 $-0.01 -6.25% 506 $0.16 $0.16 $0.16
    10 Nov 2026 $0.16 $0.00 0.00% 123,300 $0.16 $0.17 $0.16
    09 Nov 2026 $0.16 $-0.01 -6.06% 325,639 $0.16 $0.17 $0.16
    06 Nov 2026 $0.17 $0.01 6.45% 199,549 $0.16 $0.17 $0.16
    05 Nov 2026 $0.16 $0.01 6.67% 44,066 $0.16 $0.16 $0.16
    04 Nov 2026 $0.15 $-0.01 -6.25% 81,181 $0.16 $0.16 $0.15
    03 Nov 2026 $0.16 $0.01 6.67% 119,167 $0.15 $0.16 $0.15
    02 Nov 2026 $0.15 $-0.01 -6.45% 163,167 $0.15 $0.15 $0.14
    30 Oct 2026 $0.16 $0.01 6.67% 200,756 $0.15 $0.16 $0.15
    29 Oct 2026 $0.15 $0.01 6.90% 46,395 $0.16 $0.16 $0.16
    28 Oct 2026 $0.15 $0.00 0.00% 22,023 $0.14 $0.15 $0.14
    27 Oct 2026 $0.14 $-0.01 -6.45% 57,321 $0.16 $0.16 $0.14
    26 Oct 2026 $0.16 $-0.01 -6.25% 209,042 $0.16 $0.16 $0.15
    23 Oct 2026 $0.16 $0.01 6.45% 59,261 $0.16 $0.17 $0.16
    22 Oct 2026 $0.16 $0.00 0.00% 60,350 $0.17 $0.17 $0.16
    21 Oct 2026 $0.16 $0.00 0.00% 47,973 $0.16 $0.16 $0.15
    20 Oct 2026 $0.16 $0.00 0.00% 10,815 $0.16 $0.16 $0.16

    Director Transactions Data provided by Morningstar.

    Data provided by Morningstar.
    Date Director Type Amount Value Notes
    14 Sep 2026 Camile Farah Expiry 595,981 $95,356
    As advised by the company. Rights lapsed
    14 Sep 2026 Camile Farah Exercise 595,981 $95,356
    Conversion of securities. 595,981 Performance Rights
    14 Sep 2026 Camile Farah Buy 595,981 $95,356
    Conversion of securities.
    09 Sep 2026 Ronnie (Ron) Song Issued 230,502 $34,575
    Conversion of securities. nil consideration, value at closing of trading on the day of issue was $0.15 per Share
    09 Sep 2026 Ronnie (Ron) Song Exercise 230,502 $34,575
    Conversion of securities. nil consideration, value at closing of trading on the day of issue was $0.15 per Share
    07 Sep 2026 Robert Cooke Exercise 419,094 $62,864
    Conversion of securities. Nil consideration
    07 Sep 2026 Robert Cooke Issued 419,094 $62,864
    Conversion of securities. Nil consideration
    22 May 2026 Ronnie (Ron) Song Sell 3,000,000 $360,000
    Off-market trade.
    13 Jan 2026 Ronnie (Ron) Song Issued 230,502 $20,745
    Issue of securities. Performance Rights were issued for nil
    consideration. The Company values each
    Performance Right at $0.12147, 230,502 Performance Rights
    13 Jan 2026 Robert Cooke Issued 419,094 $37,718
    Issue of securities. 419,094 Performance Rights, Performance Rights were issued for nil
    consideration. The Company values each
    Performance Right at $0.12147
    13 Jan 2026 Karen Borg Issued 230,502 $20,745
    Issue of securities. Performance Rights were issued for nil
    consideration. The Company values each
    Performance Right at $0.12147, 230,502 Performance Rights
    13 Jan 2026 Camile Farah Issued 1,191,962 $107,276
    Issue of securities. Performance Rights were issued as an incentive for nil consideration. The
    Company values each Performance Right at $0.12147. 1,191,962 Performance Rights
    13 Jan 2026 Camile Farah Issued 6,157,719 $554,194
    Issue of options. Options were issued as an incentive for nil consideration. The Company values each B Option at $0.07838.
    19 Dec 2025 Karen Borg Transfer 210,365 $17,881
    Off-market transfer. As per announcement on 29-12-2025

    Directors & Management Data provided by Morningstar.

    Data provided by Morningstar.
    Name Title Start Date Profile
    Mr Ronnie (Ron) Song Non-Executive Director Feb 2021
    Mr Song had a 25-year business career in Australia. Ron has established a network of business contacts in areas of enterprise in Asia and Australia. He has contacts in the health sector in Asia as well as associations with businesses and the financial sector in Australia and Asia of value to Optiscan. He is a member of risk committee.
    Mr Robert Cooke Non-Executive ChairmanNon-Executive Director Apr 2021
    Mr Cooke has 40 year career in the health industry, his experience spans executive leadership of publicly listed and privately owned healthcare companies, and management of private and public hospitals in Australia, Asia and the UK. Robert is currently the Managing Director of Connelly Partners. Before establishing Connelly Partners in 2018, Robert was the Managing Director & CEO of Healthscope, a private hospital/medical centre/pathology operator between 2010 and 2017. Robert has served as a Director of ASX listed and private equity owned health care companies within Australia and internationally and currently serves as Non-Executive Chair of Genesis Cancer Care, and Midas Healthcare. He is a member of Risk committee.
    Ms Karen Borg Non-Executive Director Jul 2021
    Ms Borg has held senior roles in FTSE 100-250 and ASX listed companies in medical devices and consumer products as well as government and not-for-profit human and financial services. Karen has held several Chief Executive Officer positions, including Catholic Healthcare Ltd, Healthdirect and Jobs for NSW. She is a chair of Risk Committee.
    Dr Camile Farah Chief Executive OfficerManaging Director May 2021
    Dr Farah is a healthcare executive, clinician-scientist, and global authority in digital diagnostics and precision oncology, with over 25 years of experience leading transformational change across medtech, life sciences, and academic healthcare. He has held CEO, Board, and C-suite roles in medtech and diagnostic companies, commercial strategy, capital raising, global market expansion, and regulatory approvals.
    Mr Russell Low Non-Executive Director Nov 2026
    Mr Low is President and Singapore Country Head of the Clermont Group, a Singapore-headquartered international business group founded by New Zealand-born entrepreneur Richard Chandler. Mr Low leads group governance, organisational development and portfolio oversight. He brings direct experience in leading and transforming healthcare organisations. From 2019 to 2021 he was Executive Chairman of Hoan My Medical Corporation. He also served on the board of The Medical City in the Philippines from 2018 to 2022. A lawyer by training, Mr Low served in the Singapore Supreme Court and the Attorney-Generals Chambers before joining Clermont.
    Ms Elissa Hansen Company Secretary Feb 2025
    -
    Darius Ooi CFO
    -
    Elissa Hansen Company Secretary
    -

    Top Shareholders Data provided by Morningstar.

    Data provided by Morningstar.
    Name Shares Capital
    Peters Investments Pty Ltd 395,035,401 37.83%
    HSBC Custody Nominees (Australia) Limited 195,806,546 18.75%
    Citicorp Nominees Pty Limited 45,393,860 4.35%
    Ibsen Pty Ltd (Narula Family Set No. 3 A/C) 38,500,000 3.69%
    Mr Chris Graham and Mrs Diane Graham (C & D Graham S/F A/C) 13,041,000 1.25%
    Dixson Trust Pty Limited 10,592,838 1.01%
    Kebin Nominees Pty Ltd 8,480,599 0.81%
    Mr Camile Farah and Ms Marie Matias (Farah & Matias Family A/C) 8,184,849 0.79%
    BNP Paribas Noms Pty Ltd 7,267,386 0.78%
    BNP Paribas Noms Pty Ltd UOBKH A/C R Miers 6,000,888 0.70%
    Mr Kah Chin Lee 5,000,000 0.57%
    Ibsen Pty Ltd (Ibsen Superfund A/C) 4,219,007 0.48%
    Mr Anthony Mark Van Der Steeg 4,209,448 0.40%
    Mr Christopher John Martin 4,134,260 0.40%
    Mr Wally Knezevic 3,515,741 0.40%
    Miss Annabelle Jane Porter 3,515,741 0.33%
    Sash Pty Ltd (Knezevic Super Fund A/C)i 3,471,837 0.34%
    Mr James Raymond John Porter 3,431,837 0.33%
    Mr Jubran William Toak and Mr Melhem William Toak 3,422,996 0.33%
    Sash Pty Ltd (Knezevic Super Fund A/C)ii 3,422,223 0.33%

    Profile

    since

    Note